Results 171 to 180 of about 38,526 (184)

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

Lancet Oncology, The, 2011
Phillipe Moreau, Sebastian Grosicki, Xavier Leleu   +2 more
exaly  

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

New England Journal of Medicine, 2016
Antonio Palumbo, Katja C Weisel, Ajay K Nooka   +2 more
exaly  

Bortezomib

Reactions Weekly, 2017
openaire   +2 more sources

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

New England Journal of Medicine, 2017
Michel M Attal, Xavier Leleu, Karim Belhadj   +2 more
exaly  

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Lancet Oncology, The, 2019
Paul G Richardson, Albert Oriol, Fredrik Hellem Schjesvold   +2 more
exaly  

Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial

Lancet Oncology, The, 2017
Hartmut Goldschmidt, Ruben Niesvizky, Douglas Joshua   +2 more
exaly  

Bortezomib

Reactions Weekly, 2021
openaire   +1 more source

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

New England Journal of Medicine, 2018
María-Victoria Mateos, Michele Cavo, 鈴木 憲史   +2 more
exaly  

Targeting Apoptosis Pathways in Cancer Therapy

Ca-A Cancer Journal for Clinicians, 2005
exaly  

Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma

New England Journal of Medicine, 2005
Paul G Richardson, Pieter Sonneveld, Thierry Facon   +2 more
exaly